The clinical and basic pharmacology of mivacurium: a short-acting nondepolarizing benzylisoquinolinium diester neuromuscular blocking drug. Review uri icon

Overview

abstract

  • Mivacurium is a benzylisoquinolinium diester. The drug is a nondepolarizing relaxant which is hydrolysed by plasma cholinesterase at 70-88% of the rate of suxamethonium. Enzymatic hydrolysis gives the drug its short duration of action. The length of paralysis is about 2-2.5 times that of suxamethonium and one-half to one-third that of the intermediate-acting nondepolarizers. The development of mivacurium represents a collaboration between industrial pharmacologists and chemists at Burroughs Wellcome Co. (USA) and investigators at the Massachusetts General Hospital, Boston, MA, USA.

publication date

  • January 1, 1995

Research

keywords

  • Isoquinolines
  • Neuromuscular Nondepolarizing Agents

Identity

Scopus Document Identifier

  • 0029096982

PubMed ID

  • 8533538

Additional Document Info

volume

  • 106